Arcus Biosciences (NYSE:RCUS) Stock Gets Price Target Trim from Wedbush

Key Points

• Wedbush cut its Arcus Biosciences price target from $49 to $45 but maintained an “outperform” rating; the new target implies 132.87% upside from the prior close.
• Analyst sentiment is broadly positive: MarketBeat reports a “Moderate Buy” consensus, with 12 Buy, three Hold, and one Sell rating, and a consensus price target of $39.27.
• Arcus reported a quarterly loss of $1.00 per share, missing estimates of a $0.89 loss. Revenue of $9 million topped one estimate but fell 65.4% year over year.

Arcus Biosciences (NYSE:RCUS - Get Free Report) had its price target cut by analysts at Wedbush from $49.00 to $45.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Wedbush's target price indicates a potential upside of 132.87% from the stock's previous close.

A number of other analysts have also recently issued reports on the company. Citigroup boosted their price objective on Arcus Biosciences from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Wednesday, October 21st. Wall Street Zen cut Arcus Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday, October 24th. William Blair started coverage on Arcus Biosciences in a research report on Friday, October 16th. They issued an "outperform" rating for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Arcus Biosciences in a research note on Thursday, October 15th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Arcus Biosciences in a report on Friday, September 11th. Twelve research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $39.27.

Arcus Biosciences Price Performance

Shares of Arcus Biosciences stock opened at $19.32 on Thursday. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.82 and a quick ratio of 3.82. The company has a market cap of $2.46 billion, a PE ratio of -4.95 and a beta of 1.04. The firm has a fifty day moving average price of $24.26 and a two-hundred day moving average price of $24.58. Arcus Biosciences has a fifty-two week low of $17.43 and a fifty-two week high of $31.74.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.11). Arcus Biosciences had a negative net margin of 393.16% and a negative return on equity of 89.54%. The firm had revenue of $9.00 million for the quarter, compared to the consensus estimate of $7.58 million. During the same quarter in the prior year, the firm earned ($1.27) earnings per share. The company's revenue was down 65.4% on a year-over-year basis. Analysts expect that Arcus Biosciences will post -3.55 EPS for the current year.

Insiders Place Their Bets

In other news, CAO Alexander Azoy sold 2,827 shares of the company's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $30.00, for a total value of $84,810.00. Following the sale, the chief accounting officer directly owned 39,581 shares in the company, valued at approximately $1,187,430. This represents a 6.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.60% of the company's stock.

Hedge Funds Weigh In On Arcus Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of RCUS. BlackRock Inc. acquired a new stake in shares of Arcus Biosciences during the second quarter worth approximately $506,113,000. Parkman Healthcare Partners LLC acquired a new position in shares of Arcus Biosciences in the 2nd quarter worth approximately $28,341,000. Bank of America Corp DE acquired a new position in shares of Arcus Biosciences in the 2nd quarter worth approximately $25,759,000. Bank of New York Mellon Corp acquired a new position in shares of Arcus Biosciences in the 2nd quarter worth approximately $16,741,000. Finally, Renaissance Technologies LLC grew its position in Arcus Biosciences by 1,198.8% during the 1st quarter. Renaissance Technologies LLC now owns 424,700 shares of the company's stock worth $9,174,000 after acquiring an additional 392,000 shares during the last quarter. Institutional investors own 92.89% of the company's stock.

More Arcus Biosciences News

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Analysts’ average price target is reported at $39.64, well above the stock’s recent trading level. Price targets are estimates, not guarantees. Article: Arcus Biosciences Stock Has Average Target Price of $39.64 According to Analysts
• Neutral Sentiment: Arcus provided a pipeline update alongside its results. The available report excerpt mentions October HIF-2 data but does not provide enough detail to assess the update’s potential impact. Article: Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update
• Negative Sentiment: Third-quarter loss was $1.00 per share, missing the cited consensus estimate of a $0.89 loss. Revenue was $9 million—above one reported estimate of $7.58 million, but down 65.4% from a year earlier. The loss did narrow from $1.27 per share in the prior-year quarter. Article: Arcus Biosciences Reports Q3 Loss

Arcus Biosciences Company Profile

Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company uses its research platform to discover and advance medicines designed to target immune suppression and other biological mechanisms involved in tumor growth.

Arcus's oncology pipeline has included antibody-based and small-molecule therapies aimed at targets such as TIGIT, PD-1, CD73, and the adenosine A2A and A2B receptors. Its key development programs have included domvanalimab, zimberelimab, quemliclustat, and etrumadenant, which have been evaluated in clinical studies across several cancer types, including lung, gastrointestinal, and colorectal cancers.

Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical-development activities intended to support potential commercialization in international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.